A kind of antitumor composition inhalation powder spray and preparation method thereof

A technology for inhaling powder mist and composition, which is applied in the field of pharmaceutical preparations, and can solve problems such as low bioavailability, insufficient anticancer efficacy, and large toxic and side effects of VCR

Active Publication Date: 2022-08-09
ZHUHAI RESPROLY PHARM TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In general, the prior art generally has the problems of insufficient anticancer efficacy, large toxic and side effects of VCR and low bioavailability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of antitumor composition inhalation powder spray and preparation method thereof
  • A kind of antitumor composition inhalation powder spray and preparation method thereof
  • A kind of antitumor composition inhalation powder spray and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] The experimental materials and methods used in the examples are as follows:

[0041] Experimental cells: human T lymphocytic leukemia cells (Jurkat), human breast cancer cells (MCF-7), retinoblastoma cell line (HXO-Rb44).

[0042] Growth medium: RPMI-1640 medium (containing 10% FBS+1% PS).

[0043] Culture environment: 37°C, 5% CO 2 Saturated humidity incubator.

[0044] Human T lymphocytic leukemia cells (Jurkat), human breast cancer cells (MCF-7), and retinoblastoma cell lines (HXO-Rb44) in logarithmic growth phase and in good shape were washed once with PBS buffer and added Digest with 0.25% trypsin solution and gently pipet to a single cell suspension. Pipette 20 μl of the cell suspension to a cell counting plate for cell counting. The above cell suspension was 1×10 cells 4 The density of cells / well was inoculated into 96-well plates, with 5 duplicate wells in each group, at 37°C, 5% CO. 2 The cells were cultured in a saturated humidity incubator for 24 h to m...

Embodiment 2

[0054] NOD-SCID mice were randomly divided into control group (with normal saline), VCR group, nimodipine group and VCR-nimodipine combination group, 10 mice in each group. 7.5Gy dose given to mice 60 After 5 days of whole-body irradiation with Coγ rays, human T lymphocytic leukemia cells (Jurkat) in logarithmic growth phase and in good shape were taken, washed three times with PBS buffer, digested with 0.25% trypsin solution, and gently pipetted to make them Drop off, add 12ml RPMI-1640 medium, transfer the suspension to a 15ml centrifuge tube, and centrifuge at 1000rpm for 5min. The supernatant was discarded, and the pelleted cells were washed with sterile saline and diluted. Take 40 μl of cell suspension for microscopic examination and count, and make a concentration of 1×10 6 cells / ml of tumor cell suspension, 0.2ml / cell was injected into the tail vein. The mice were observed for leukemia symptoms after inoculation with Jurkat cells, and the drug was administered on the...

Embodiment 3

[0060] (a) Take 3.0g of VCR and 25g of nimodipine and carry out ultrafine jet pulverization respectively, set the injection pressure of 7bar, the pulverization pressure of 5bar, and the feed rate of 0.4g / min to obtain micronized VCR (D10=1.29 μm, D50=3.62 μm, D90=6.49 μm, NLT96.44%<10 μm) and nimodipine (D10=1.48 μm, D50=3.75 μm, D90=6.76 μm, NLT96.12%<10 μm). Mix VCR 0.8g (micropowder), nimodipine 12g (micropowder), mannitol 50g and leucine 0.4g, place the mixed sample in a high-speed mixing granulator, set the stirring speed to 1300rpm, and finish after mixing for 20min. After settling for 1 h, the resulting dry powder mixture was filled into No. 3 dark vegetable capsules in aliquots.

[0061] (b) get 3.0g VCR and 0.03g leucine and mix, get 25g nimodipine and 0.25g leucine and mix, the above-mentioned two mixtures are respectively carried out ultrafine jet pulverization according to the parameter of embodiment 3 step (a), A mixture of micronized VCR (D10=1.13 μm, D50=3.05 μ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The present invention disclosed a antitumor composition inhalation of pink fogging agent: composed of the following weights: 100-500 copies of new alkali sulfuric acid, 500 to 30,000 copies of Nimo Horizon, 2500 to 40,000 copies of the carrier, 2 additional agents 2~ 2000 copies; and the particle size of the sulfuric acid Changchun, Nimo Horizon, and the carrier of the sulfuric acid; and the additional particles of the additional agent at least 98 % of the particle size are less than 50 μm according to the weight.The present invention also provides preparation methods for the pink fog agent, including ‑: microfifling the sulfuric acid Changchun, Nimo Horizon and additional agent;; Mix the microcoperly drugs, carrier particles and additional agents; fill the mixture with a trace capsule with a trace capsule in a deep -colored plant capsule, and make the powder mist capsule.The present invention can enhance the efficacy of anti -cancer, reduce the toxic side effects of VCR, and improve biological utilization.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to an anti-tumor composition inhalation powder aerosol, especially an anti-tumor composition inhalation powder aerosol and a preparation method thereof. Background technique [0002] Tumor is a new organism formed by abnormal proliferation of tissue cells at the gene level under the action of various carcinogenic factors, and it has become a common chronic disease. Tumors are generally divided into two categories: benign and malignant. According to the World Health Organization, in 2018, there were 18.1 million new cancer cases and 9.6 million deaths worldwide, further increasing the global cancer burden. Before the age of 75, the cumulative risk of developing cancer was 21.4%, the risk of dying from cancer was 17.7%, and the five-year survival rate, the number of people still alive after five years of illness, was estimated at 43.8 million. It is estimated tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/72A61K47/10A61K9/14A61K31/475A61P35/00A61K31/4422
CPCA61K31/475A61K31/4422A61K9/0075A61K9/145A61P35/00A61K2300/00
Inventor 陈永奇陈浩璇胡芳
Owner ZHUHAI RESPROLY PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap